Managed Access Program (MAP) Cohort Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Feb 2021 New trial record